ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment comprises of the immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 2, 2006 and is headquartered in Hackensack, NJ.
ADMA call option trades that are bought on or above the market's asking price OR put trades that are sold on or less than the market's bid price - expecting a move to the updside.
ADMA put option trades that are bought on or above the market's asking price OR call trades that are sold on or less than the market's bid price - expecting a move to the downside.